Related Experiment Video
Updated: Aug 1, 2026
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
STAT3-decoy oligodeoxynucleotide inhibits the growth of human lung cancer via down-regulating its target genes
Xulong Zhang1, Jian Zhang, Haiming Wei
1Institute of Immunopharmacology and Immunotherapy, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, PR China.
Abstract:
Double-stranded decoy oligodeoxynucleotide (ODN) is a promising approach for inhibiting gene transcription. Signal transducer and activator of transcription (STAT) 3, a potent transcription factor, is usually constitutively activated in a variety of malignancies, and considered as an attractive drug target. In this study, it was noted that STAT3 was overactivated in human lung cancer cells, and STAT3-decoy ODN, which was high-efficiently transfected into nucleus of cancer cells, significantly inhibited the proliferation of PG cells by inducing apoptosis or cell cycle arrest. The transcription levels of mcl-1, cyclin D1, bcl-xl and survivin were significantly decreased by 64.4, 56.1, 72.8% (P<0.01) and 31.8% (P<0.05), respectively; and the synthesis levels of bcl-xl and cyclin D1 in PG cells showed 64.5% (P<0.01) and 28.6% (P<0.05) decrease, respectively. Our study demonstrated that decoy-ODN targeting at activated STAT3 may potentially be used as an anti-lung cancer therapeutic approach.
Insights
STAT3-decoy oligodeoxynucleotide (ODN) effectively inhibits lung cancer cell proliferation by inducing apoptosis and cell cycle arrest. This targeted approach shows potential as an anti-lung cancer therapy.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- Signal transducer and activator of transcription (STAT) 3 is a key transcription factor often overactivated in cancers.
- STAT3 dysregulation contributes to tumor development and progression, making it a significant drug target.
- Lung cancer exhibits overactivation of STAT3, necessitating targeted therapeutic strategies.
Purpose of the Study:
- To investigate the efficacy of STAT3-decoy oligodeoxynucleotide (ODN) in inhibiting human lung cancer cell proliferation.
- To evaluate the impact of STAT3-decoy ODN on apoptosis, cell cycle arrest, and the expression of key oncogenes.
Main Methods:
- Transfection of STAT3-decoy ODN into human lung cancer cells (PG cells).
- Assessment of cell proliferation, apoptosis, and cell cycle progression.
- Quantification of transcription and synthesis levels of target genes including mcl-1, cyclin D1, bcl-xl, and survivin.
Main Results:
- STAT3-decoy ODN significantly inhibited PG cell proliferation by inducing apoptosis and cell cycle arrest.
- Significant reductions were observed in transcription levels of mcl-1 (64.4%), cyclin D1 (56.1%), bcl-xl (72.8%), and survivin (31.8%).
- Synthesis levels of bcl-xl and cyclin D1 were decreased by 64.5% and 28.6%, respectively.
Conclusions:
- STAT3-decoy ODN demonstrates potent anti-lung cancer activity by targeting the overactivated STAT3 pathway.
- This approach offers a promising therapeutic strategy for lung cancer treatment.
- Further research into decoy-ODN targeting STAT3 is warranted for clinical applications.
